A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

NCT02421939 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

371

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Acute Myeloid (AML)

Interventions

DRUG: gilteritinib
DRUG: LoDAC (Low Dose Cytarabine)
DRUG: Azacitidine
DRUG: MEC (Mitoxantrone, Etoposide, Cytarabine)
DRUG: FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)

Sponsor

Astellas Pharma Global Development, Inc.